Literature DB >> 15312960

Species-specific immune response to immunization with human versus rodent A beta peptide.

Timothy J Seabrook1, Jeanne K Bloom, Melitza Iglesias, Edward T Spooner, Dominic M Walsh, Cynthia A Lemere.   

Abstract

Amyloid beta (A beta) immunization of amyloid precursor protein (APP)-transgenic (tg) mice with human A beta induces humoral immunity, however, the immune response to endogenous rodent A beta is unknown. Fourteen-month J20 APP-tg mice and non-tg littermates were immunized subcutaneously followed by chronic intranasal boosting with human or rodent A beta peptide and adjuvant LT(R192G). Rodent A beta-immunized APP-tg mice had anti-rodent A beta antibody levels of 257.8 micrograms/ml and those immunized with human A beta had anti-human A beta antibodies of 120.8 micrograms/ml. Non-tg littermates had anti-rodent and anti-human A beta antibody concentrations of 98.8 and 231.1 microgram/ml, respectively. Inter-species cross-reactivity was minimal. Anti-human A beta antibodies were predominately IgG1 and IgG2b, while anti-rodent A beta antibodies were equally IgG1, IgG2a, and IgG2b. Anti-human A beta antibodies recognized an epitope within human A beta1-9. Anti-rodent A beta antibodies did not stain Alzheimer's disease (AD) plaques but bound some plaques in APP-tg mice. Splenocytes proliferated modestly to their respective antigen and secreted low levels of IL-2 and IFN-gamma. Therefore, immunizing APP-tg and non-tg mice with rodent A beta resulted in a species-specific humoral response with modest T cell reactivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312960     DOI: 10.1016/j.neurobiolaging.2003.12.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  11 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

Review 2.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

3.  Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.

Authors:  D M Wilcock; P T Jantzen; Q Li; D Morgan; M N Gordon
Journal:  Neuroscience       Date:  2006-11-28       Impact factor: 3.590

4.  Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.

Authors:  Michal Arbel; Iftach Yacoby; Beka Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

5.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

6.  Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

Authors:  Donna M Wilcock; Amyn Rojiani; Arnon Rosenthal; Gil Levkowitz; Sangeetha Subbarao; Jennifer Alamed; David Wilson; Nedda Wilson; Melissa J Freeman; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

7.  Intranasal delivery of human beta-amyloid peptide in rats: effective brain targeting.

Authors:  Eszter Sipos; Anita Kurunczi; András Fehér; Zsuzsa Penke; Lívia Fülöp; Agnes Kasza; János Horváth; Sándor Horvát; Szilvia Veszelka; Gábor Balogh; Levente Kürti; István Eros; Piroska Szabó-Révész; Arpád Párducz; Botond Penke; Mária A Deli
Journal:  Cell Mol Neurobiol       Date:  2009-10-06       Impact factor: 5.046

8.  Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

Authors:  Marcel Maier; Timothy J Seabrook; Noel D Lazo; Liying Jiang; Pritam Das; Christopher Janus; Cynthia A Lemere
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

9.  Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice.

Authors:  Timothy J Seabrook; Liying Jiang; Katelyn Thomas; Cynthia A Lemere
Journal:  J Neuroinflammation       Date:  2006-06-05       Impact factor: 8.322

10.  Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons.

Authors:  Yoichi Kondo; Cynthia A Lemere; Timothy J Seabrook
Journal:  J Neuroinflammation       Date:  2007-12-20       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.